# FDA Takes Serious Action Against Sarepta After Third Patient Death Linked to Elevidys Gene Therapy

> news · REPORTED · 2025-07-23

The FDA took serious regulatory action against Sarepta Therapeutics following reports of a third patient death associated with Elevidys, its Duchenne muscular dystrophy gene therapy, prompting Roche to voluntarily suspend Elevidys shipments to some international markets as well.

About Sarepta Therapeutics: Sarepta Therapeutics is a biopharmaceutical company focused on precision genetic medicine for rare neuromuscular diseases, including Duchenne muscular dystrophy, and markets Elevidys, a gene therapy approved by the FDA.

- Company: Sarepta Therapeutics
- Sector: therapeutics
- Primary source: https://www.biospace.com/archive/2025-07-23?p=1

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.